Novel strategies to lower Lp(a)
Video navigation menu
- Pathophysiology 00:39
- RNA therapeutics for Lp(a) therapy 02:21
- Early studies with antisense mediated Lp(a) lowering 05:26
- AKCEA-APO(a)-Lrx phase 2 trials 13:07
- CV outcome trial targeting Lp(a) 13:40
This presentation by prof. Sam Tsimikas, MD was part of the EBAC-accredited symposium "Lp(a), a new lipid frontier in CV risk management and target for therapy" held during the virtual ESC Congress 2020
Sam Tsimikas, Professor of Medicine and Director of Vascular Medicine at the University of California San Diego School of Medicine, San Diego, CA, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Sanofi and Novartis.
This is available as accredited online CME for members. Click the button below to enroll:Enroll